

AMANDA LOCHNER:

PUBLICATIONS (2004 - 2013)

1. Huisamen B, Upton J, van Zyl D, Lochner A. A role for the alphaadrenergic signalling pathway in the response of the papillary muscles from type 2 diabetes to anoxia-reoxygenation. *Cardiovasc drugs Therap* 2004; 18: 247-255
2. Strijdom, H., Genade, S., Hartley, S., Lochner, A. Nitric oxide generated in isolated cardiomyocytes does not contribute to classic preconditioning. *Cardiovasc Drugs and Therap* 2004; 18: 99-112.
3. Huisamen, B., Lochner, A. Exercise modulated myocardial protein kinase B/Akt in Zucker obese rats. *Heart* 2005; 91: 227-228.
4. Engelbrecht, A-M., Niesler, C., Spangenberg, B., Page, C., Doubell, A., Lochner, A. Inhibition of stress activated protein kinases (SAPKs) attenuates hypoxia/reoxygenation-induced apoptosis in neonatal cardiomyocytes. *Bas Res Cardiol* 2004; 99: 338-350.
5. Strijdom, H., Muller, C., Lochner, A. Direct intracellular nitric oxide (NO) detection in isolated adult cardiomyocytes: flow cytometric analysis, using the fluorescent probe, diaminofluorescein (DAF). *J Mol Cell Cardiol.* 2004; 37: 897-902.
6. Du Toit, E.F., Rossouw, E., Van Rooyen, J., Lochner, A. Proposed mechanisms for anabolic steroid induced cardiac hypertrophy and increased susceptibility in ischaemic/reperfusion injury. *SA Cardiovascular J* 2004; 15: 166-173.
7. Marais E, Genade S, Salie R, van Wyk J, Moolman JA, Lochner A. The temporal relationship between p38MAPK and HSP27 activation in ischaemic and pharmacological preconditioning. *Bas Res Cardiol.* 2005; 100: 35-47.
8. Lochner A, du Toit EF, Huisamen B, Koeslag JH, Moolman JA, Van Rooyen J. Cellular injury in ischaemia. Editorial. *Cardiovascular Journal of Southern Africa* 2004; 15: 205-6.
9. Makaula, S., Lochner A, Genade S, Sack, MN, Awan MM, Opie, LH. H-89, a non-specific inhibitor of protein kinase A, promotes postischemic contractile recovery and reduces infarct size. *Cardiovasc Pharmacol* 2005; 45: 341-347.

10. Du Toit EF, Rossouw E, Opie LH, Lochner A. Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. *Cardiovasc Drugs and Therapy* 2005; 19: 23-31.
11. Du Toit EF, McNabben M, Lochner A. A potential role of angiotensin II in obesity-induced cardiac hypertrophy and ischaemia-reperfusion injury. *Basic Res Cardiol*. 2005; 100: 1-9.
12. Du Toit, E.F., Rossouw, E., Opie, L.H, Lochner, A. The effect of sildenafil on reperfusion, infarct size and cyclic nucleotide levels in the isolated rat heart model. *Cardiovasc Drugs & Therap* 2005; 19: 23-31.
13. Engelbrecht, A-M., Page, C, Niesler, C, Lochner, A. Long-chain polyunsaturated fatty acids attenuate hypoxia/reoxygenation-induced apoptosis in neonatal cardiomyocytes via MAPK-dependent pathways. *J Mol Cell Cardiol* 2005: 39: 940-954.
14. Engelbrecht, A-M., Esterhuyse, J., du Toit, E.F., Lochner, A., van Rooyen, J. p38 MAPK and PKB/Akt, possible role players in red palm oil-induced protection of the isolated perfused rat heart. *J Nutr Biochem* 2006; 17: 265-271.
15. Lochner, A., Genade, S., Davids, A., Ytrehus, K., Moolman, J.A. Short and long term effects of melatonin on the response of the heart to ischaemia-reperfusion injury. *J Pineal Res* 2006: 40: 5663.
16. Strijdom, H., Jacobs, S., Muller, C., Page, C., Lochner, A. Baseline and hypoxia-induced NO production in isolated cardiomyocytes and cardiac microvascular endothelial cells: a comparative study. *FASEB J*. 2006: 20: 314-316.
17. Moolman, J.A., Hartley, S., Marais, E., van Wyk, J., Genade, S., Lochner, A. Attenuation of p38MAPK activation by preconditioning causes a reduction in myocardial necrosis and apoptosis. *Cardiovasc Drugs Therap*. 2006: 20: 13-25.
18. Arvola, L., Bertelsen, E., Lochner, A., Ytrehus, K. Sustained antibeta-adrenergic effect of melatonin in guinea pig heart papillary muscle. *Scand Cardiovasc J* 2006: 40: 37-42.
19. Genade, S., Ytrehus, K., Lochner, A. Melatonin prevents cardioprotection induced by a multi-cycle ischaemic preconditioning protocol in rats. *Cardiovasc J of SA* 2006; 17; 239244.

20. Lochner, A, Moolman JA. The many faces of H89: a review. *Cardiovascular Drug Reviews* 2006; 24: 261-274.
21. Du Toit, Genade S, Carlini S, Moolman JA, Brunner F, Lochner A. Efficacy of ischaemic preconditioning in the eNOS overexpressed working mouse heart model. *Europ J Pharmacol* 2007; 556: 115 - 120.
22. Moolman, J.A., Marais, E., Genade, S., Makaula, S., Lochner, A. The role of the beta adrenergic signal transduction pathway in myocardial protection. In: *Signal transduction in health and disease*. Ed A & M Srivastava. Springer Verlag, 2008.
23. Du Toit EF, Genis A, Pollesello P, Opie LH, Lochner A. Levosimendan. A role for the RISK pathway and K(ATP) channels in pre- and postconditioning induced by levosimendan in the isolated guinea pig heart. *Br J Pharmacol* 2008; 154:41-50
24. Marais E, Genade S., Lochner A. CREB activation and ischaemic preconditioning. *Cardiovasc Drugs & Therapy* 2008; 22:3-17.
25. Huisamen B, Genade S, Lochner A. Signalling pathways activated by glucagon-like peptide 1 (7-36) amide in the rat heart and the rat heart and their role in protection against ischaemia. *Cardiovasc J Africa* 2008; 19: 77-83.
26. Du Toit EF, Smith W, Muller C, Strijdom H, Stouthammer B, Woodiwiss AJ, Norton GR, Lochner A. Myocardial susceptibility to ischemic-reperfusion injury in a prediabetic model of dietary-induced obesity. *Am J Physiol Heart Circ Physiol* 2008; 294: H2336-2343.
27. Van Vuuren D, Genis A, Genade S, Lochner A. Postconditioning the isolated working rat heart. *Cardiovasc Drugs Ther* 2008; 22: 391397.
28. Lochner A. Sarcolemmal permeability changes during ischaemia and reperfusion: release of survival factors. *Cardiovasc Res* 2008; 79: 545-546.
29. Genade S, Genis A, Ytrehus K, Huisamen B, Lochner A. Melatonin receptor-mediated protection against myocardial ischaemia/reperfusion injury: role of its anti-adrenergic actions. *J Pineal Res* 2008; 45: 449-458.
30. Van Vuuren D, Lochner A. Ischaemic postconditioning: from bench to bedside. *Cardiovasc J Africa* 2008; 19: 311-320.

31. Strijdom H, Friedrich SO, Hattingh S, Chamane N, Lochner A. Hypoxia-induced regulation of nitric oxide synthase in cardiac endothelial cells and the role of the PI3-K/PKB pathway. *Mol Cell Biochem* 2009; 321:23-35.
32. Lochner A, Marais E, Genade S, Huisamen B, du Toit EF, Moolman JA. Protection of the ischaemic heart : investigations into the mechanism of ischaemic preconditioning. *Cardiovasc J Africa* 2009; 20: 45-53.
33. Strijdom H, Chamane N, Lochner A. Nitric oxide in the cardiovascular system: a simple molecule with complex actions. *Cardiovasc J Afr* 2009; 20: 275-282.
34. Strijdom H, Lochner A. Cardiac Endothelium: More than just a barrier (Review). *SA Heart* 2009; 6: 174-185.
35. Fan W-J, Genade S, Genis A, du Toit EF, Huisamen B, Lochner A. Dexamethasone-induced cardioprotection: a role for the phosphatase MKP-1 ? *Life Sciences* 2009; 84: 838-846.
36. Webster I, Friedrich SO, Lochner A., Huisamen B. AICAR and ZMP unmask differential effects of AMP kinase on GLUT4 translocation and insertion in the membranes of isolated cardiomyocytes. *Cardiovasc J Afr* 2010; 21: 72-78
37. Fan W-J, Van Vuuren D, Genade S, Lochner A. Kinases and phosphatases in ischaemic preconditioning: a re-evaluation. *Bas Res Cardiol* 2010; 105: 495-511
38. Webster I, Friedrich SO, Lochner A, Huisamen B. AMPkinase activation and glut4 translocation in isolated cardiomyocytes. *Cardiovasc J Afr* 2010; 21: 72-78
39. Huisamen B, Pêrel S, Friedrich SO, Strijdom H, Lochner A. Ang II receptor antagonism improves nitric oxide production, eNOS and PKB expression in hearts from a model of insulin resistance. *Mol Cell Biochem* 2011; 349: 21-31
40. Huisamen B, Genis A, Lochner A. Pretreatment with a DPP-4 inhibitor is infarct sparing in hearts from obese prediabetic rats. *Cardiovasc Drugs Therap* 2011; 25:13-20
41. Huisamen B, Lochner A. GSK-3 protein and the heart - friend or foe? *SA Heart* 2010; 7:49-57.

42. Nduhirabandi F, Du Toit EF, Lochner A. Chronic melatonin consumption prevents obesity and related metabolic abnormalities and protects the heart against ischaemia and reperfusion injury in a prediabetic model of diet-induced obesity. *J Pineal Res* 2011; 50:171-182
43. Clark C, Smith W, Lochner A, du Toit EF. Effects of gender and obesity on myocardial tolerance to ischaemia. *Physiol Res* 2011; 60: 291-301
44. McCarthy J, Lochner A, Opie LH, Sack MN, Essop MF. PKC ϵ promotes cardiac mitochondrial and metabolic adaptation to chronic hypobaric hypoxia by GSK3 β inhibition. *J Cell Physiol* 2011; 226: 2457-2468
45. Salie R, Moolman JA, Lochner A. The role of beta-adrenergic receptors in the cardioprotective effects of beta-preconditioning (BPC). *Cardiovasc Drugs Therap* 2011; 25: 31-46
46. Lochner A. Signalling during an ischaemic preconditioning protocol: new role players? *Cardiovasc Res* 2011; 90: 5-6
47. Loos B, Genade S, Ellis B, Lochner A, Engelbrecht A-M. At the core of survival: autophagy delays the onset of both apoptotic and necrotic cell death in a model of ischemic cell injury. *Exp Cell Res* 2011; 317: 1437-1453
48. Loos B, Lochner A, Engelbrecht A-M. Autophagy in heart disease: a strong hypothesis for an untouched metabolic reserve. *Med Hypotheses* 2011; 77: 52-57
49. George C, Lochner A, Huisamen B. The efficacy of *Prosopis glandulosa* as antidiabetic treatment in rat models of diabetes and insulin resistance. *J Ethnopharmacol* 2011; 137: 298-304
50. McCarthy J, Lochner A, Opie LH, Sack MN, Essop MF. PKCepsilon promotes cardiac mitochondrial and metabolic adaptation to chronic hypobaric hypoxia by GSK3beta inhibition. *J Cell Physiol* 2011; 226: 2457-2468
51. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity associated abnormalities. *Acta Physiol (Oxf)* 2012; 205: 209-223
52. Maarman G, Marais E, Lochner A, du Toit EF. Effect of chronic CPT-1 inhibition on myocardial ischemia-reperfusion injury (I/R) in a

- model of diet-induced obesity. *Cardiovasc Drugs Therap* 2012; 26: 205-216
53. Mudau M, Genis A, Lochner A, Strijdom JG. Endothelial dysfunction: the early predictor of atherosclerosis. *Cardiovasc J Africa* 2012; 23: 222-231
 54. Huisamen B, Dietrich D, Bezuidenhout N, Lopes J, Flepisi B, Blackhurst D, Lochner A. Early cardiovascular changes occurring in diet-induced, obese insulin-resistant rats. *Mol Cell Biochem* 2012; 368: 37-45
 55. Webster I, du Toit EF, Huisamen B, Lochner A. The effect of creatine supplementation on myocardial function, mitochondrial respiration and susceptibility to ischaemia/reperfusion injury in sedentary and exercised rats. *Acta Physiol* 2012; 206: 6-19
 56. Salie R, Moolman JA, Lochner A. The mechanism of beta-adrenergic preconditioning: roles for adenosine and ROS during triggering and mediation. *Bas Res Cardiol* 2012; 107: 281-285
 57. Lochner A, Huisamen B, Nduhirabandi F. Cardioprotective effect of melatonin against ischaemia/reperfusion damage. *Front Biosc* 2013; 5: 305-315.
 58. Flepisi TB, Lochner A, Huisamen B. The consequences of long-term glycogen synthase kinase-3 inhibition on normal and insulin resistant rat hearts. *Cardiovasc Drugs Therap* 2013; 27: 381-392.
 59. Webster I, Smith A, Lochner A, Huisamen B. Sanguinarine: non-versus re-circulation during isolated heart perfusion- a Jekyll and Hyde effect? *Cardiovasc Drugs Therap* 2014; 28: 489-491.
 60. Nduhirabandi F, Huisamen B, Strijdom H, Blackhurst D, Lochner A. Short-term melatonin consumption protects the heart of obese rats independent of body weight change and visceral adiposity. *J Pineal Res* 2014; 57: 317-332.
 61. Salie R, Huisamen B, Lochner A. High carbohydrate and high fat diets protect the heart against ischaemia/reperfusion injury. *Cardiovasc Diabetol* 2014; 13: 109.
 62. Espach Y, Lochner A, Strijdom H, Huisamen B. ATM protein kinase signalling, type 2 diabetes and cardiovascular disease. *Cardiovasc Drugs Therap* 2015; 29: 51-58.
 63. Smith W, Norton GR, Woodiwiss AJ, Lochner A, du Toit EF. Dependence of cardiac systolic function on elevated fatty acid

- availability in obese insulin-resistant rats. *J Cardiac Fail* 2016; 22: 560-568.
64. Huisamen B, Hafner TL, Lumkwana D, Lochner A. The impact of chronic glycogen synthase kinase 3-inhibition on normal and pre-diabetic rat hearts. *Cardiovasc Drugs Therap* 2016; 30: 237-246.
 65. Van Vuuren D, Marais E, Genade S, Lochner A. The differential effects of FTY720 on functional recovery and infarct size following myocardial ischaemia/reperfusion. *Cardiovasc J Afr* 2016; 27: 375-386.
 66. Salie R, Lochner A, Loubser D. The significance of the washout period in preconditioning. *Cardiovasc Ther* 2017; 35:doi 10.1111/1755-5922.12252.
 67. Webster I, Salie R, Marais E, Fan WJ, Maarman G, Huisamen B, Lochner A. Myocardial susceptibility to ischaemia/reperfusion in obesity: a re-evaluation of the effects of age. *BMC Physiol* 2017; 17: 3.
 68. Webster I, Smith A, Lochner A, Huisamen B. The role of MKP-1 in insulin-induced cardioprotection. *Cardiovas Drugs Therap* 2017; 31: 247-254.
 69. Nduhirabandi F, Huisamen B, Strijdom H, Lochner A. Role of melatonin in glucose uptake by cardiomyocytes from insulin-resistant Wistar rats. *Cardiovasc J Afr* 2017; 28: 362-369.
 70. Lochner A, Marais E, Huisamen B. Melatonin and cardioprotection against ischaemia/reperfusion injury. What's new? A review. *J Pineal Res* 2018; 65: 212490.
 71. Everson F, Genis A, Ogundipe T, de Boever P, Goswami N, Lochner A, Blackhurst D, Strijdom H. Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz associated with cardioprotection in high calorie diet-induced obese rats. *PLoS One* 2018; 13: e0208537.
 72. Salie R, Alsalhin AKH, Marais E, Lochner A. Cardioprotective effects of beta3-adrenergic receptor (β 3-AR) Pre, Per- and Post-treatment in ischaemia/reperfusion. *Cardiovasc Drugs Therap* 2019; 33: 163-177.
 73. Driescher N, Joseph DE, Human VR, Ojuka E, Cour M, Hadebe N, Bester D, Marnewick JL, Lecour S, Lochner A, Essop MF. The impact of sugar-sweetened beverage intake on rat cardiac function. *Heliyon* 2019; 5: e01592.

74. Smit M, Coetzee AR, Lochner A. The pathophysiology of myocardial ischemia and perioperative myocardial infarction. *J Cardiothorac Vasc Anesth* 2019; pii: S1053-0770(19)31038-9.
75. Dube K, Dhanabalan K, Salie R, Blignaut M, Huisamen B, Lochner A. Melatonin has profound effects on mitochondrial dynamics in myocardial ischaemia/reperfusion. *Heliyon* 2019; 5: 202659.
76. Dhanabalan K, Huisamen B, Lochner A. Mitochondrial oxidative phosphorylation and mitophagy in myocardial ischaemia/reperfusion: effects of chloroquine. *Cardiovasc J Afr* 2019; 30: 1-11.